3rd generation glp-1 LY3437943, a novel triple glucagon, GIP, and receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept Emerging Frontiers in GLP-1 Therapeutics:

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial

Seyfried introduces the Glucose Ketone Index as a tool for monitoring metabolic health and discusses metabolic therapies including ketogenic diets and fasting that target cancer cells' energy dependencies

These strategies aim to address different aspects of metabolic dysfunction while building on the proven benefits of incretin-based therapy

The following are considered non-clear fluids : Milk* and cream (including in tea or coffee) Non-dairy whiteners such as almond, soy, or oat milk Soluble fibre Broths Jelly *Breast milk can be given up to 3 hours before the procedure